The nineteen analysts that follow CVS Health Co (NYSE: CVS) have given the stock a rating of “Moderate Buy” as the consensus recommendation for the stock, as indicated by Bloomberg Ratings.
Two analysts have recommended that investors maintain their current holdings in the company, while fourteen others have given it a buy rating the stock, as indicated by Bloomberg Ratings.
Two analysts have recommended that investors maintain their current holdings in the company, while fourteen others have given it a buy rating.
The stock currently has a price target of $119.65, the average price target that brokers who graded the stock in the previous year have set for the stock for the next 12 months.
A sizeable number of shareholders have been active buyers and sellers of company stock throughout the most recent period.
During the third quarter, Diversified Trust Company increased the proportion of CVS Health stock owned by one-hundredth of one percent.
In the most recent fiscal quarter, Diversified Trust Company successfully acquired an additional 145 shares, bringing the total number of shares owned directly by the company to 14,899.
The total value of these shares comes to $1,421,000.
In the third quarter, Carnegie Capital Asset Management LLC made a 28.9% purchase of additional CVS Health stock, bringing the total amount of the company’s CVS Health stock ownership to 100%. Following the conclusion of the most recent quarterly acquisitions, Carnegie Capital Asset Management LLC now directly owns 55,867 pharmacy operator shares, valued at $5,328,000.
The amount of CVS Health common stock that Bond & Devick Financial Network INC owned as of the end of the third quarter was up 1.9% compared to the beginning of the quarter.
After purchasing an additional 200 shares during the most recent quarter, Bond & Devick Financial Network INC now has 10,820 of the pharmacy operator’s shares, valued at a total of $1,032,000.
These shares were acquired to bring the total number of shares owned by the company up to 10,820. Royal London Asset Management Ltd increased the proportion of CVS Health stock owned by 1.3% during the second quarter of 2018. Royal London Asset Management Ltd now has 470,446 shares of the drugstore operator’s stock, worth a combined total of $43,601,000 after purchasing an additional 6,045 shares during the most recent quarter.
This brings the company’s total number of shares to 470,446.
And finally, during the three months ending in September, Ritholtz Wealth Management increased the amount of CVS Health stock owned by 107.8 percent. Ritholtz Wealth Management increased its ownership of the drugstore operator’s stock by purchasing an additional 13,813 shares during the most recent fiscal quarter, bringing its total ownership of the company’s stock to 26,627 shares with a value of $2,539,000. Seventy-seven point two percent of the total number of shares outstanding in the company are held by institutional investors and hedge funds.
Recently, a number of market analysts have shared their perspectives on the stock regarding their recommendations.
In a research report released on February 9th, Jefferies Financial Group raised its price target for CVS Health shares from $130.00 to $143,000.
The report was about the company’s expectations for future growth.
Additionally, the st